Mr. Mishustin spoke about the goals of the “New Health Saving Technologies” national project.

list

“The main objective of the national project will be the introduction of new medical technologies, assistance in conducting clinical studies and trials with subsequent registration and launch of promising diagnostic and treatment methods, drugs, medical devices and products on the market. Including the results of work in the field of regenerative biomedicine and tissue engineering,” the Prime Minister of the Russian Federation noted.

Mikhail Mishustin reported that over the five months of this year, the growth in the production of medicines and medical materials approached 8%. “And the national project is designed to support this trend,” the head of the Cabinet said.

As part of the “New Health Saving Technologies” national project, the development of 25 gene therapy drugs and personalized cellular products, as well as 11 products based on artificial intelligence, will be ensured. 10 new technologies to prevent and correct cognitive impairment and 10 technologies to reduce the burden of cell aging will be created.

The goals of the national project fit well with the updated development strategy of Artgen Biotech (MOEX: ABIO) for 2024-2026. According to this strategy, the company will form a portfolio of 10 new drugs intended for the treatment of genetic, age-dependent, infectious and oncological diseases.

According to Sergei Masyuk, Director of Artgen Biotech, the company’s ecosystem accelerates biotech startups and helps group companies develop and commercialize new drugs. “Artgen Biotech plans to support up to 30 early developments of innovative drugs from molecular design to the proof of concept in animal models. Of these, it is planned to obtain 10 candidate drugs by 2026 for the subsequent launch of 5-6 drugs on the market, and 1 to 3 blockbuster drugs are expected from those obtained.”